Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab

Hideo Oishi; Ryota Morimoto; Yoshie Shimoyama; Kei Kuroda; Toru Urata; Toru Kondo; Takahiro Okumura; Yasuko K. Bando; Masashi Akiyama; Toyoaki Murohara

doi:10.1016/j.jaccas.2020.07.028

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab

Hideo Oishi
, Ryota Morimoto
, Yoshie Shimoyama
, Kei Kuroda
, Toru Urata
, Toru Kondo
, Takahiro Okumura
, Yasuko K. Bando
, Masashi Akiyama
, Toyoaki Murohara

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Recent developments in immune checkpoint inhibitors (ICIs) have provided new treatment strategies for advanced cancer. However, ICIs lead to an imbalance between T cell–mediated inflammatory responses and immune tolerance in the myocardium. Here we report the first case that implicates the contribution of ICI-induced vasculitis to myocardial injury. (Level of Difficulty: Intermediate.)

Original language	English
Pages (from-to)	1937-1941
Number of pages	5
Journal	JACC: Case Reports
Volume	2
Issue number	12
DOIs	https://doi.org/10.1016/j.jaccas.2020.07.028
Publication status	Published - 10-2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jaccas.2020.07.028

Cite this

@article{f2e06cc0c0bd47f09eb7850b6761f0b3,

title = "Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab",

abstract = "Recent developments in immune checkpoint inhibitors (ICIs) have provided new treatment strategies for advanced cancer. However, ICIs lead to an imbalance between T cell{\textendash}mediated inflammatory responses and immune tolerance in the myocardium. Here we report the first case that implicates the contribution of ICI-induced vasculitis to myocardial injury. (Level of Difficulty: Intermediate.)",

keywords = "myocardial injury, pembrolizumab, vasculitis",

author = "Hideo Oishi and Ryota Morimoto and Yoshie Shimoyama and Kei Kuroda and Toru Urata and Toru Kondo and Takahiro Okumura and Bando, \{Yasuko K.\} and Masashi Akiyama and Toyoaki Murohara",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

month = oct,

doi = "10.1016/j.jaccas.2020.07.028",

language = "English",

volume = "2",

pages = "1937--1941",

journal = "JACC: Case Reports",

issn = "2666-0849",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab

AU - Oishi, Hideo

AU - Morimoto, Ryota

AU - Shimoyama, Yoshie

AU - Kuroda, Kei

AU - Urata, Toru

AU - Kondo, Toru

AU - Okumura, Takahiro

AU - Bando, Yasuko K.

AU - Akiyama, Masashi

AU - Murohara, Toyoaki

PY - 2020/10

Y1 - 2020/10

N2 - Recent developments in immune checkpoint inhibitors (ICIs) have provided new treatment strategies for advanced cancer. However, ICIs lead to an imbalance between T cell–mediated inflammatory responses and immune tolerance in the myocardium. Here we report the first case that implicates the contribution of ICI-induced vasculitis to myocardial injury. (Level of Difficulty: Intermediate.)

AB - Recent developments in immune checkpoint inhibitors (ICIs) have provided new treatment strategies for advanced cancer. However, ICIs lead to an imbalance between T cell–mediated inflammatory responses and immune tolerance in the myocardium. Here we report the first case that implicates the contribution of ICI-induced vasculitis to myocardial injury. (Level of Difficulty: Intermediate.)

KW - myocardial injury

KW - pembrolizumab

KW - vasculitis

UR - https://www.scopus.com/pages/publications/85092456804

UR - https://www.scopus.com/pages/publications/85092456804#tab=citedBy

U2 - 10.1016/j.jaccas.2020.07.028

DO - 10.1016/j.jaccas.2020.07.028

M3 - Article

AN - SCOPUS:85092456804

SN - 2666-0849

VL - 2

SP - 1937

EP - 1941

JO - JACC: Case Reports

JF - JACC: Case Reports

IS - 12

ER -

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this